Table S1. Characteristics of study subjects

| Donor exposure(s) | Natural infection | | | | mRNA vaccine | | Natural infection plus mRNA vaccine | |
|---|-------------------|-------------|------------|------------|---------------------|----------------------|--|-----------------------------|
| | D614G | B.1.429 | B.1.1.519 | E484K | BNT162b2 vaccine | mRNA-1273 vaccine | D614G + BNT162b2 | B.1.429 + BNT162b2 |
| Count | n = 10 | n = 15 | n = 6 | n = 2 | n = 5 | n = 6 | n = 8 | n = 17 |
| Mean age (SD) | 48.8 (12.6) | 42.0 (11.2) | 37.5 (7.3) | 32.5 (2.1) | 32.4 (11.3) | 29.8 (6.9) | 43.9 (12.3) | 40.5 (9.2) |
| Sex | | | | | | | | |
| Female (%) | 5 (50%) | 10 (66.7%) | 4 (66.7%) | 0 (0%) | 4 (66.6%) | 2 (40%) | 1 (12.5%) | 9 (52.9%) |
| Male (%) | 5 (50%) | 5 (33.3%) | 2 (33.3%) | 2 (100%) | 2 (33.3%) | 3 (60%) | 7 (87.5%) | 8 (47.1%) |
| Symptoms | | | | | | | | |
| Yes (%) | 8 (80.0%) | 9 (60.0%) | 4 (66.7%) | 2 (100%) | | | 5 (62.5%) | 9 (52.9%) |
| No (%) | 2 (20.0%) | 5 (33.3%) | 2 (33.3%) | 0 (0.0%) | | | 2 (25.0%) | 7 (41.2%) |
| Unknown (%) | 0 (0.0%) | 1 (6.7%) | 0 (0.0%) | 0 (0.0%) | | | 1 (12.5%) | 1 (5.9%) |
| Days post COVID19+ (SD) Days post vaccine (SD) | 56 (19.1) | 38.7 (6.1) | 38.5 (8.9) | 36 (11.3) | 16 (2.8) | 35 (13.3) | 116 (11.2) 19.5 (6.9) | 107.1 (13.2) 28.4 (13.1) |